drugset / Trial / NCT00652288

Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs

NCT00652288

Phase 1 Completed 36 enrolled Yale University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate the variations in pharmacokinetic and pharmacodynamic properties of rapid-acting insulin analogs when given as a bolus by subcutaneous insulin infusion pump as typically encountered in the care of children with type 1 diabetes. The specific factors under investigation are: * the effects of puberty * type of insulin analog * site of catheter insertion * and age of catheter

Timeline

Start
2007-04
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic 0.2 iu/kg Subcutaneous
Comparator insulin aspart Protein / enzyme biologic 0.2 iu/kg Subcutaneous
Comparator insulin detemir Protein / enzyme biologic 0.4 iu/kg
Comparator insulin glargine Protein / enzyme biologic 0.4 iu/kg